CJC-1295 / Ipamorelin 10mg / 5mg Research Peptide
This is a single-vial co-formulation of CJC-1295 (a GHRH analog) and Ipamorelin (a selective GHRP / ghrelin agonist). Together they trigger a pulsatile release of endogenous growth hormone that more closely mimics natural physiology than either peptide alone.
Purity
99.4% HPLC-tested purity with COA support.
Size
10mg / 5mg Lyophilized Powder.
Storage
-20°C (Freezer)
Research use
For laboratory research use only. Not for human or veterinary use.
Mechanism of action
CJC-1295 binds the GHRH receptor on the anterior pituitary, increasing the amplitude of growth hormone pulses. Ipamorelin binds the GHSR (ghrelin receptor) and amplifies pulse frequency without elevating prolactin, cortisol or ACTH — a cleaner profile than older GHRPs.
Research applications
- Growth hormone secretagogue research
- Sleep architecture and REM studies
- Lean mass and body composition research
- Recovery and protein synthesis studies
- IGF-1 axis pharmacology
Frequently asked questions
Why blend CJC-1295 with Ipamorelin?
Research uses both because CJC-1295 increases GH pulse amplitude (GHRH pathway) and Ipamorelin increases pulse frequency (ghrelin pathway). The combination produces stronger, more physiological GH release than either alone.
Does Ipamorelin raise cortisol or prolactin?
Ipamorelin is the most selective of the GHRPs. Published literature shows no clinically meaningful elevation of cortisol, prolactin or ACTH — its main differentiator from GHRP-2 and GHRP-6.
Is this CJC-1295 with or without DAC?
This blend uses CJC-1295 without DAC (also called Modified GRF 1-29). It produces short ~30-minute pulses ideal for pairing with Ipamorelin.
Browse research peptides for sale · View lab reports · Read peptide FAQ